PMC4508379 Pickart, L., et al
Two years ago, researchers examining the link between GLP-1 and substance abuse began to publish large, observational studies showing that patients taking GLP-1s for their prescribed purposes incidentally reported less alcohol, opioid, cannabis and cigarette use and had a lower risk of developing a substance use disorder
In 2025, the American Diabetes Association updated their recommendations and said that Ozempic and other GLP-1s should be considered as a first line therapy for certain high-risk patients
although semaglutide did not increase the survival of ganglion cells, it significantly improved the fractal dimension of astrocytes and their lacunarity [72]
Springer: Berlin, 1988
These important interactions are beyond the scope of this initial investigation, but will be incorporated in future studies